Fate Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview

Fate Therapeutics

11/08/2026 12:03

Fate Therapeutics Inc FATE.OQ FATE.O is expected to  show a fall in quarterly revenue when it reports  results on August 13 (estimated) for the period ending June 30 2026
The San Diego California-based  company is expected to report a 28.4% decrease in revenue to $1.366 million from $1.91 million a year ago, according to the mean estimate from 12 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Fate Therapeutics Inc is for a loss of 27 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Fate Therapeutics Inc is $6.50, about 135.5% above its last closing price of $2.76
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.27
-0.28
-0.26
Beat
7.1
Dec. 31 2026
-0.27
-0.27
-0.27
Met
-0.1
Sep. 30 2025
-0.28
-0.29
-0.27
Beat
7.2​
Jun. 30 2025
-0.34
-0.34
-0.29
Beat
15.3
​​Mar. 31 2025
-0.38
-0.38
-0.32
Beat
16.4
Dec. 31 2024
-0.43
-0.43
-0.44
Missed
-1.7​
Sep. 30 2024
-0.41
-0.43
-0.40
Beat
7.5
Jun. 30 2024
-0.47
-0.48
-0.33
Beat
30.6
This summary was machine generated August 11 at 11:03 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)